IgG-cleaving cysteine protease (IdeS)Hansa Biopharma

Imlifidase

Imlifidase is an IgG-cleaving enzyme (IdeS) that removes circulating IgG within hours. Hansa Biopharma evaluated it for rapidly clearing pathogenic autoantibodies in anti-GBM disease (the GOOD-IDES-02 study).

Also known as: IDEFIRIX, IdeS

Forecast a trial in the Arena Browse all benchmarks

Trials tracked

Resolved

Indications

Targets

Imlifidase forecasting benchmarks

1 benchmark

ResolvedPhase 3

GOOD-IDES-02 (imlifidase) Phase 3 anti-GBM

Imlifidase · Anti-GBM disease

Dec 16, 2025Clinical Trials

Mechanism & molecular targets

IgG / IdeS· pathway

Indications studied

Anti-GBM disease

Developed by

Hansa Biopharma· HNSA

About Imlifidase

What is Imlifidase?

What does Imlifidase target?

Imlifidase acts on Pathogenic IgG (IdeS cleavage).

How well do AI models predict Imlifidase trial outcomes?

Open any benchmark below to see the full model leaderboard scored by accuracy, Brier score, and log loss. Models forecast each readout before it is public, so the scores reflect genuine predictive skill rather than hindsight.